|
GB8531071D0
(en)
*
|
1985-12-17 |
1986-01-29 |
Boots Co Plc |
Therapeutic compound
|
|
AU721924B2
(en)
*
|
1992-06-23 |
2000-07-20 |
Sepracor, Inc. |
Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
|
|
EP0647134A4
(en)
*
|
1992-06-23 |
1997-07-30 |
Sepracor Inc |
METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
|
|
GB9311920D0
(en)
|
1993-06-09 |
1993-07-28 |
Pfizer Ltd |
Therapeutic agents
|
|
US5459164A
(en)
*
|
1994-02-03 |
1995-10-17 |
Boots Pharmaceuticals, Inc. |
Medical treatment
|
|
DE19518988A1
(de)
*
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
|
|
GB9619757D0
(en)
|
1996-09-21 |
1996-11-06 |
Knoll Ag |
Chemical process
|
|
GB9619961D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
|
GB9619962D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
|
GB9727131D0
(en)
|
1997-12-24 |
1998-02-25 |
Knoll Ag |
Therapeutic agents
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6046242A
(en)
*
|
1998-11-27 |
2000-04-04 |
Basf Aktiengesellschaft |
Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
|
|
US6696495B2
(en)
*
|
1998-12-02 |
2004-02-24 |
Snowden Pharmaceuticals, Llc |
Treatment of disorders secondary to organic impairments
|
|
US6323242B1
(en)
|
1998-12-02 |
2001-11-27 |
Peter Sterling Mueller |
Treatment of disorders secondary to organic impairments
|
|
BG65170B1
(bg)
*
|
1999-03-17 |
2007-05-31 |
Knoll Gmbh |
Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
|
|
WO2000056309A1
(en)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Method of treating sexual dysfunction
|
|
MXPA01009464A
(es)
*
|
1999-03-19 |
2004-03-19 |
Abbott Gmbh & Co Kg |
Metodo para el tratamiento de apnea de sueno.
|
|
JP2002539252A
(ja)
*
|
1999-03-19 |
2002-11-19 |
クノール・ゲー・エム・ベー・ハー |
胆石の治療
|
|
US6803387B1
(en)
|
1999-03-19 |
2004-10-12 |
Abbott Gmbh & Co. Kg |
Treatment of neuropathic pain or fibromyalgia
|
|
AU3895400A
(en)
*
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Control of metabolism
|
|
DE60039508D1
(de)
*
|
1999-03-19 |
2008-08-28 |
Abbott Gmbh & Co Kg |
Methoden zur behandlung der essstörungen
|
|
CA2367021A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Knoll Gmbh. |
Method of controlling weight gain associated with therapeutic drugs
|
|
AU3894500A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Prevention of cardiovascular disease
|
|
AU3760600A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Treatment of orthostatic hypotension
|
|
US6552087B1
(en)
|
1999-03-19 |
2003-04-22 |
Abbott Gmbh & Co. Kg |
Therapeutic agent comprising (+)-sibutramine
|
|
WO2000056321A1
(en)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Treatment of hyperactivity disorders
|
|
WO2000056312A1
(en)
|
1999-03-19 |
2000-09-28 |
Knoll Gmbh |
Treatment of pulmonary hypertension
|
|
KR20010113848A
(ko)
*
|
1999-03-19 |
2001-12-28 |
독터. 호르스트 하스칼, 잉에 린스 |
임신 후 체중 감량
|
|
EP1169027A4
(en)
*
|
1999-03-19 |
2004-10-20 |
Abbott Gmbh & Co Kg |
TREATMENT OF ARTHROSIS
|
|
WO2000056310A1
(en)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Treatment of chronic fatigue syndrome
|
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
GB9926251D0
(en)
*
|
1999-11-06 |
2000-01-12 |
Knoll Ag |
Pharmaceutical formulation
|
|
GB0004003D0
(en)
*
|
2000-02-22 |
2000-04-12 |
Knoll Ag |
Therapeutic agents
|
|
AU2001282913A1
(en)
*
|
2000-09-08 |
2002-03-22 |
Eli Lilly And Company |
A method of treating weight gain associated with atypical antipsychotic use
|
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
|
US6610887B2
(en)
|
2001-04-13 |
2003-08-26 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
|
ATE486842T1
(de)
*
|
2002-03-12 |
2010-11-15 |
Merck Sharp & Dohme |
Substituierte amide
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
US20050131074A1
(en)
*
|
2003-08-04 |
2005-06-16 |
Beckman Kristen M. |
Methods for treating metabolic syndrome
|
|
JP4765627B2
(ja)
|
2003-09-22 |
2011-09-07 |
Ｍｓｄ株式会社 |
新規ピペリジン誘導体
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
KR100830002B1
(ko)
|
2005-01-06 |
2008-05-15 |
씨제이제일제당 (주) |
시부트라민의 무기산염
|
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
|
BRPI0610580B8
(pt)
|
2005-05-30 |
2021-05-25 |
Banyu Pharma Co Ltd |
composto derivado de piperidina
|
|
JPWO2007018248A1
(ja)
|
2005-08-10 |
2009-02-19 |
萬有製薬株式会社 |
ピリドン化合物
|
|
DE602006017712D1
(de)
|
2005-08-24 |
2010-12-02 |
Banyu Pharma Co Ltd |
Phenylpyridonderivat
|
|
JPWO2007029847A1
(ja)
|
2005-09-07 |
2009-03-19 |
萬有製薬株式会社 |
二環性芳香族置換ピリドン誘導体
|
|
EP1938811A4
(en)
*
|
2005-09-22 |
2008-12-17 |
Eisai R&D Man Co Ltd |
MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
|
|
EP1940842B1
(en)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
US8911751B2
(en)
*
|
2005-10-11 |
2014-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions for nasal delivery
|
|
CA2625416A1
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
|
JPWO2007049798A1
(ja)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
新規ベンゾオキサチイン誘導体
|
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
|
US8748419B2
(en)
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
|
RU2477634C2
(ru)
*
|
2006-06-16 |
2013-03-20 |
Теракос, Инк. |
Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
|
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
|
US7989500B2
(en)
|
2006-09-15 |
2011-08-02 |
Reviva Pharmaceuticals, Inc. |
Synthesis, methods of using, and compositions of cycloalkylmethylamines
|
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
CA2664358A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diarylketimine derivative
|
|
WO2008124122A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent and glitazones
|
|
JP2010523659A
(ja)
*
|
2007-04-09 |
2010-07-15 |
サイドース・エルエルシー |
スタチン類と抗肥満症薬との組み合わせ
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
|
JP5508258B2
(ja)
|
2007-06-04 |
2014-05-28 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
トリアリール化合物および前記化合物を含む組成物
|
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2714617A1
(en)
|
2008-03-06 |
2009-09-11 |
Banyu Pharmaceutical Co., Ltd. |
Alkylaminopyridine derivative
|
|
EP2272841A1
(en)
|
2008-03-28 |
2011-01-12 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
|
|
JPWO2009154132A1
(ja)
|
2008-06-19 |
2011-12-01 |
Ｍｓｄ株式会社 |
スピロジアミン−ジアリールケトオキシム誘導体
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
AU2009277736A1
(en)
|
2008-07-30 |
2010-02-04 |
Banyu Pharmaceutical Co., Ltd. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
|
CN102264228A
(zh)
|
2008-10-22 |
2011-11-30 |
默沙东公司 |
用于抗糖尿病药的新的环状苯并咪唑衍生物
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US20100311710A1
(en)
*
|
2008-12-06 |
2010-12-09 |
Auspex Pharmaceuticals, Inc. |
Cyclobutanemethanamine inhibitors of monoamine reuptake
|
|
WO2010075068A1
(en)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
|
EP2379562A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
WO2012003501A2
(en)
|
2010-07-02 |
2012-01-05 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
EP2677869B1
(en)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
|
WO2014130608A1
(en)
|
2013-02-22 |
2014-08-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
EP3004138B1
(en)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2015068156A1
(en)
|
2013-11-05 |
2015-05-14 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
|
AU2015308350B2
(en)
|
2014-08-29 |
2020-03-05 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
|
KR20190065312A
(ko)
|
2016-10-14 |
2019-06-11 |
테스 파마 에스.알.엘. |
알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제
|
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC SPIROCHROMAN COMPOUNDS
|
|
AU2019385644A1
(en)
|
2018-11-20 |
2021-06-03 |
Tes Pharma S.R.L. |
Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase
|